NASDAQ$ABOS

Acumen Pharmaceuticals Inc · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Headline financials

Total Revenue

$151K

No prior period
EPS (adj)

-$0.07

No prior period
R&D expenses

$1.9M

No prior period
G&A expenses

$300K

No prior period
Net Income

-$2.04M

No prior period
Operating Income

-$2.04M

No prior period
Gross Profit

-$1.78M

No prior period
R&D Expense

$1.93M

No prior period

Revenue & EPS history

Acumen · Revenue · Quarterly

$151K

Q2 2020
Beat estimate in 0 of 1 quarters(0%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports

Historical avg

+0.6%

Avg return

Earnings day

-3.4%

Avg return

5 days after

-6.1%

Avg return

30 days after

42%

8 / 19 earnings

Positive

+35.9%

Q1 2023

Best reaction

-21.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.5%-11.7%
Q4 2025-2.3%-10.3%-2.3%
Q3 2025-1.5%-19.8%+8.6%
Q1 2025+0.0%+1.9%+8.6%
Q4 2024+6.0%-7.3%-6.9%
Q3 2024-21.4%-25.5%-35.7%
Q2 2024-1.6%+0.4%-4.3%
Q1 2024+13.1%+8.6%-21.4%
Q4 2023-3.5%+8.0%-20.6%
Q3 2023+12.1%+20.0%+53.2%
Q2 2023-3.1%+2.0%-19.9%
Q1 2023+35.9%+15.5%+0.4%
Q4 2022+2.3%+3.6%-4.1%
Q3 2022-5.1%-10.6%-15.3%
Q2 2022+4.6%-11.5%+9.4%
Q1 2022+9.6%+4.5%+7.8%
Q4 2021-14.8%-22.0%-22.2%
Q3 2021-17.1%-23.9%-46.7%
Q2 2021+1.6%+13.9%+1.1%
Q1 2021
Q4 2020
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro